Clinical Trial Search Results

Filter Results

Age group

Category

Primary purpose

Study type

Location

Search results

You can use the filters to refine your search.

Displaying 1 - 20 of 30

Open Actively Recruiting

Influenza and other Viruses in the acutelY ill: Adult Inpatient SARS-CoV-2 Vaccine Effectiveness Surveillance

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Contact: TREVOR FRANKEL
Open Actively Recruiting

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery

Prospective multi-center phase 2b randomized placebo-controlled double-blinded interventional platform trial of two different pharmacologic therapies (intravenous Vitamin C or intravenous Acetaminophen) for patients with sepsis-induced hypotension or respiratory failure.

Phase: Phase 2
Primary Purpose: Treatment
Gender: All
Contact: HENA SIHOTA
Open Actively Recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency

The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 144 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in participants with Alpha1-Antitrypsin Deficiency (AATD).

Phase: Phase I/II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Donghyun Jung
Open Actively Recruiting

SPIROMICS Study of Early COPD Progression (SOURCE)

This is an observational study of 600 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals.

The study has three main goals: - To use CT scan imaging to identify which smokers will develop COPD. - To identify biomarkers predictive of smokers that will develop COPD. - To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study related questionnaires assessing medical history, smoke exposure and use, medication use, social and behavioral health, pulmonary symptoms, food frequency, and will provide nasal swab, blood, stool, and urine samples, pulmonary function testing to determine function, sputum induction to provide a sputum sample for airway biospecimen analysis, and CT imaging of the lungs.

Gender: All
Contact: Roslynn Marzan-McGill
Open Actively Recruiting

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

This is a Phase 2, multicenter, double-blind, randomized (1:1), placebo-controlled, 12-week, proof-of-concept study to evaluate the safety and tolerability as well as the mechanistic effect of oral administration of alvelestat (MPH966) in subjects with confirmed AATD defined as PiZZ, PiSZ, Pi*null, or another rare phenotype/genotype known to be associated with either low (serum AAT level <11 μM or <57.2 mg/dL) or functionally impaired AAT including "F" or "I" mutations.

Phase: Phase II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Donghyun Jung
Open Actively Recruiting

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC.

Phase: Phase 3
Primary Purpose: Treatment
Gender: All
Contact: Julia Vargas
Open Actively Recruiting

Functional, imaging, and respiratory evaluation in CORAL: FIRE CORAL

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Contact: Julia Vargas
Investigator: Nida Qadir, MD
Open Actively Recruiting

Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 48 weeks.

Phase: Phase 3
Primary Purpose: Treatment
Gender: All
Contact: Maria Granone
Investigator: Tisha S. Wang, MD
Open Actively Recruiting

Adult Inpatient SARS-CoV-2 Vaccine Effectiveness Surveillance

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Nida Qadir
Investigator: Nida Qadir, MD
Open Actively Recruiting

Cystic Fibrosis Lung Transplant Consortium (CFLTC) Biorepository and Registry

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Eileen Callahan
Open Actively Recruiting

Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis

A Phase 2a, multicenter, 3-part, randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the safety, tolerability, and PK of once-daily treatment with PLN-74809 in participants with idiopathic pulmonary fibrosis.

Phase: Phase II
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Eileen Callahan
Open Actively Recruiting

Surveillance of Respiratory Viruses in the Critically Ill: 2020-2021 IVY Network Surveillance Study

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Adreanne Rivera
Investigator: Nida Qadir, MD
Open Actively Recruiting

COVID-19 Surveillance in Healthcare Workers and Patients: Observational Studies from the Influenza Vaccine Effectiveness in the Critically Ill (IVY) Network

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Age Group: Adults
Contact: Nida Qadir
Investigator: Nida Qadir, MD
Open Actively Recruiting

Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Eileen Callahan
Open Actively Recruiting

Tezepelumab COPD Exacerbation Study

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Phase: Phase 2
Primary Purpose: Treatment
Gender: All
Contact: Roslynn Marzan-McGill
Open Actively Recruiting

Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial

This is a study to determine if early, long-term low dose sirolimus is effective for preventing progression to more advanced stages.

Phase: Phase 3
Primary Purpose: Treatment
Gender: Female
Contact: Chen Zheng
Open Actively Recruiting

Revefenacin in Acute Respiratory Insufficiency in COPD

RARICO is a pragmatic, randomized, controlled, double-blinded, multi-center trial evaluating the safety and feasibility of nebulized revefenacin in comparison to nebulized ipratropium in patients with COPD and acute respiratory failure requiring invasive mechanical ventilation.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: Roslynn Marzan-McGill
Open Actively Recruiting

LAI-001, Clinical evaluation of LungLB in Subjects Presenting for Initial Biopsy; Impact on Decision Making LAI-002, Clinical evaluation of Lung LB in post-surgical monitoring.

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Phase: N/A
Age Group: Adults
Contact: Rafael Corona Jr.
Investigator:
KOSTYANTYN KRYSAN
Open Actively Recruiting

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)

The objective of the trial is to assess efficacy and safety of add-on aerosolized liposomal cyclosporine A (L-CsA) to Standard of Care (SoC) therapy as compared to SoC therapy alone in the treatment of Bronchiolitis obliterans syndrome (BOS) in double lung transplant recipients.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: ELMAN B PUNZALAN
Open Actively Recruiting

Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)

The objective of the trial is to assess efficacy and safety of add-on aerosolized liposomal cyclosporine A (L-CsA) to Standard of Care (SoC) therapy as compared to SoC therapy alone in the treatment of Bronchiolitis obliterans syndrome (BOS) in single lung transplant recipients.

Phase: Phase III
Primary Purpose: Treatment
Gender: All
Age Group: Adults
Contact: ELMAN B PUNZALAN